Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP621972.RApU9LOxJw30l5YZ-BhRdDW-VWw-SxsN_DOF6rc691cQg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP621972.RApU9LOxJw30l5YZ-BhRdDW-VWw-SxsN_DOF6rc691cQg130_assertion type Assertion NP621972.RApU9LOxJw30l5YZ-BhRdDW-VWw-SxsN_DOF6rc691cQg130_head.
- NP621972.RApU9LOxJw30l5YZ-BhRdDW-VWw-SxsN_DOF6rc691cQg130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621972.RApU9LOxJw30l5YZ-BhRdDW-VWw-SxsN_DOF6rc691cQg130_provenance.
- NP621972.RApU9LOxJw30l5YZ-BhRdDW-VWw-SxsN_DOF6rc691cQg130_assertion evidence source_evidence_literature NP621972.RApU9LOxJw30l5YZ-BhRdDW-VWw-SxsN_DOF6rc691cQg130_provenance.
- NP621972.RApU9LOxJw30l5YZ-BhRdDW-VWw-SxsN_DOF6rc691cQg130_assertion SIO_000772 20080466 NP621972.RApU9LOxJw30l5YZ-BhRdDW-VWw-SxsN_DOF6rc691cQg130_provenance.
- NP621972.RApU9LOxJw30l5YZ-BhRdDW-VWw-SxsN_DOF6rc691cQg130_assertion wasDerivedFrom befree-20150227 NP621972.RApU9LOxJw30l5YZ-BhRdDW-VWw-SxsN_DOF6rc691cQg130_provenance.
- NP621972.RApU9LOxJw30l5YZ-BhRdDW-VWw-SxsN_DOF6rc691cQg130_assertion wasGeneratedBy ECO_0000203 NP621972.RApU9LOxJw30l5YZ-BhRdDW-VWw-SxsN_DOF6rc691cQg130_provenance.